Fabian Christoph Franzeck

Fabian Christoph Franzeck

Auto-generated profile, based on publicly available information

Fabian Christoph Franzeck

University of Basel , Basel , Switzerland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in European Journal of Radiology
Verified
Journal Article
Open access
LSLena Schmuelling
Lena Schmuelling
FFFabian C. Franzeck
Fabian C. Franzeck
CNChristian Hans Nickel
Christian Hans Nickel
GMGregory Mansella
Gregory Mansella
RBRoland Bingisser
Roland Bingisser
GSGregor Sommer
Gregor Sommer
Rapid communication of CT exams positive for pulmonary embolism (PE) is crucial for timely initiation of anticoagulation and patient outcome. It is unknown if deep learning automated detection of PE on CT Pulmonary Angiograms (CTPA) in combination with worklist prioritization and an electronic notification system (ENS) can improve communication times and patient turnaround in the Emergency Department (ED). In 01/2019, an ENS allowing direct communication between radiology and ED was installed. Starting in 10/2019, CTPAs were processed by a deep learning (DL)-powered algorithm for detection of PE. CTPAs acquired between 04/2018 and 06/2020 (n = 1808) were analysed. To assess the impact of the ENS and the DL-algorithm, radiology report reading times (RRT), radiology report communication time (RCT), time to anticoagulation (TTA), and patient turnaround times (TAT) in the ED were compared for three consecutive time periods. Performance measures of the algorithm were calculated on a per exam level (sensitivity, specificity, PPV, NPV, F1-score), with written reports and exam review as ground truth. Sensitivity of the algorithm was 79.6 % (95 %CI:70.8-87.2%), specificity 95.0 % (95 %CI:92.0-97.1%), PPV 82.2 % (95 %CI:73.9-88.3), and NPV 94.1 % (95 %CI:91.4-96 %). There was no statistically significant reduction of any of the observed times (RRT, RCT, TTA, TAT). DL-assisted detection of PE in CTPAs and ENS-assisted communication of results to referring physicians technically work. However, the mere clinical introduction of these tools, even if they exhibit a good performance, is not sufficient to achieve significant effects on clinical performance measures.

1 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FFFabian C. Franzeck
Fabian C. Franzeck
RNRamadhani Ngwale
Ramadhani Ngwale
BMBernadeta Msongole
Bernadeta Msongole
MHMarian Hamisi
Marian Hamisi
OAOmary Abdul
Omary Abdul
MTMarcel Tanner
Marcel Tanner
Co-infection with hepatitis B virus (HBV) is highly prevalent in people living with HIV in Sub-Saharan Africa. Screening for HBV surface antigen (HBsAg) before initiation of combination antiretroviral therapy (cART) is recommended. However, it is not part of diagnostic routines in HIV programs in many resource-limited countries although patients could benefit from optimized antiretroviral therapy covering both infections. Screening could be facilitated by rapid diagnostic tests for HBsAg. Operating experience with these point of care devices in HIV-positive patients in Sub-Saharan Africa is largely lacking. We determined the prevalence of HBV and Hepatitis C virus (HCV) infection as well as the diagnostic accuracy of the rapid test device Determine HBsAg in an HIV cohort in rural Tanzania. Prospectively collected blood samples from adult, HIV-1 positive and antiretroviral treatment-naïve patients in the Kilombero and Ulanga antiretroviral cohort (KIULARCO) in rural Tanzania were analyzed at the point of care with Determine HBsAg, a reference HBsAg EIA and an anti-HCV EIA. Samples of 272 patients were included. Median age was 38 years (interquartile range [IQR] 32–47), 169/272 (63%) subjects were females and median CD4+ count was 250 cells/µL (IQR 97–439). HBsAg was detected in 25/272 (9.2%, 95% confidence interval [CI] 6.2–13.0%) subjects. Of these, 7/25 (28%) were positive for HBeAg. Sensitivity of Determine HBsAg was rated at 96% (95% CI 82.8–99.6%) and specificity at 100% (95% CI, 98.9–100%). Antibodies to HCV (anti-HCV) were found in 10/272 (3.7%, 95% CI 2.0–6.4%) of patients. This study reports a high prevalence of HBV in HIV-positive patients in a rural Tanzanian setting. The rapid diagnostic test Determine HBsAg is an accurate assay for screening for HBsAg in HIV-1 infected patients at the point of care and may further help to guide cART in Sub-Saharan Africa.

1 December 2020 in Radiology: Cardiothoracic Imaging
Verified
Journal Article
Closed access
MHMaurice Henkel
Maurice Henkel
TWThomas Weikert
Thomas Weikert
KMKatharina Marston
Katharina Marston
NSNathalie Schwab
Nathalie Schwab
GSGregor Sommer
Gregor Sommer
ASAlexander Sauter
Alexander Sauter
Background CT has emerged as an important diagnostic tool in COVID-19, but the underlying pathological changes behind CT findings are not yet fully elucidated. Purpose The purpose of this retrospec...

20 March 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
SDSarah Dräger
Sarah Dräger
MRMatthias von Rotz
Matthias von Rotz
NLNiklaus D Labhardt
Niklaus D Labhardt
MSMartin Siegemund
Martin Siegemund
KRKatharina M. Rentsch
Katharina M. Rentsch
FFFabian C Franzeck
Fabian C Franzeck
We analyzed the attainment of early pharmacological targets of continuous infusion meropenem and piperacillin/tazobactam and the use and effect of a real-time therapeutic drug monitoring (TDM) program on subsequent dosing and target attainment in patients who are critically ill. This was a single-center, retrospective study among patients hospitalized in the intensive care unit in a Swiss tertiary care hospital from 2017 to 2020. The primary outcome was target attainment [100% tT ≥ 4xECOFF (Pseudomonas aeruginosa)] of continuous infusion meropenem and piperacillin/tazobactam within 72 hours after initiation of treatment. A total of 234 patients were included. Median first meropenem (n = 186 of 234) and piperacillin (n = 48 of 234) concentration was 21 mg/L (interquartile range [IQR], 15.6–28.6) and 100.7 mg/L (IQR, 64.0–160.2), respectively. Pharmacological target was attained in 95.7% (95% confidence interval [CI], 91.7–98.1) of patients receiving meropenem and 77.0% (95% CI, 62.7–87.9) treated with piperacillin/tazobactam. In the univariable and multivariable logistic regression, body weight and estimated glomerular filtration rate were negatively associated with target attainment. Subsequently, meropenem dosage was decreased or stopped in 35 of 186 (18.8%) and 89 of 186 (47.9%) patients, respectively, and increased in 2 of 186 (1.1%) patients. Continuous infusion meropenem and piperacillin/tazobactam yielded excellent and moderate early pharmacological target attainment in critically ill patients, respectively. The TDM was mainly used to decrease meropenem dosage.

21 April 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
ARAndrej Romanov
Andrej Romanov
MBMichael Bach
Michael Bach
SYShan Yang
Shan Yang
FFFabian C. Franzeck
Fabian C. Franzeck
GSGregor Sommer
Gregor Sommer
ASAlexander Sauter
Alexander Sauter
CT patterns of viral pneumonia are usually only qualitatively described in radiology reports. Artificial intelligence enables automated and reliable segmentation of lungs with chest CT. Based on this, the purpose of this study was to derive meaningful imaging biomarkers reflecting CT patterns of viral pneumonia and assess their potential to discriminate between healthy lungs and lungs with viral pneumonia. This study used non-enhanced and CT pulmonary angiograms (CTPAs) of healthy lungs and viral pneumonia (SARS-CoV-2, influenza A/B) identified by radiology reports and RT-PCR results. After deep learning segmentation of the lungs, histogram-based and threshold-based analyses of lung attenuation were performed and compared. The derived imaging biomarkers were correlated with parameters of clinical and biochemical severity (modified WHO severity scale; c-reactive protein). For non-enhanced CTs (n = 526), all imaging biomarkers significantly differed between healthy lungs and lungs with viral pneumonia (all p < 0.001), a finding that was not reproduced for CTPAs (n = 504). Standard deviation (histogram-derived) and relative high attenuation area [600–0 HU] (HU-thresholding) differed most. The strongest correlation with disease severity was found for absolute high attenuation area [600–0 HU] (r = 0.56, 95% CI = 0.46–0.64). Deep-learning segmentation-based histogram and HU threshold analysis could be deployed in chest CT evaluation for the differentiating of healthy lungs from AP lungs.

30 October 2022 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
MSMihaela Sava
Mihaela Sava
VBVeronika Bättig
Veronika Bättig
SGSabine Gerull
Sabine Gerull
JPJakob R. Passweg
Jakob R. Passweg
Nina KhannaNina Khanna
Nina Khanna
SSSwiss Transplant Cohort Study
Swiss Transplant Cohort Study